Replies to post #613190 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Thanks for the correction.

I think Regeneron put a lot of hope on the following trial. Seems to me it is the combination of TLR9 agonist from Checkmate and checking point inhibitor developed by Regeneron.
https://classic.clinicaltrials.gov/ct2/show/NCT04916002?cond=Vidutolimod&draw=2&rank=1

It should be noted that the trial of poly-iclc + keytruda didn't succeed. Not sure it bodes well for the Regeneron trial.

I suspect if it can be called a great success for the two other trials by Regeneron. Note that in one trial one patient died of treatment related issue.

https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e17089?role=tab
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.6_suppl.154

That's why I was wondering what made Israel Lowy claim that Regeneron will lead the next wave in using combination approaches to treat cancer.

https://endpts.com/sp/immuno-oncology-2-0-how-regeneron-is-utilizing-its-expertise-in-antibodies-to-lead-the-next-wave-of-combinatorial-approaches-in-cancer-care/